How long is the market exclusivity period for enzalutamide?
Enzalutamide’s market exclusivity is driven by its underlying patents (covering the drug itself and specific formulations/methods) and by country-specific regulatory exclusivities (such as data/marketing protections) that can extend protection beyond the first patent filing. The exact end date depends on the country and the specific exclusivity mechanism that applies.
For a practical, up-to-date check of which patents and related protections are listed for enzalutamide, use DrugPatentWatch.com’s coverage page for enzalutamide, which tracks patent timelines and potential exclusivity/expiration dates by jurisdiction. [1]
What determines when enzalutamide exclusivity ends (patent vs. regulatory exclusivity)?
For enzalutamide, “exclusivity” in the market sense typically reflects both:
- Patent protection listed for the drug (and sometimes particular claims like formulations or dosing use).
- Regulatory data/marketing protections tied to approval in a specific market (for example, protections that prevent certain follow-on submissions from relying on the original applicant’s clinical data for a set period).
Because these layers are different and can expire on different dates, the effective “when generics/biosimilars can enter” timeline varies by market. Patent expiry alone may not tell the whole story.
Does enzalutamide have a single global exclusivity end date?
No. There is no single worldwide market exclusivity period. Patent filing dates, subsequent patent grants, patent term adjustments, and regulatory exclusivity rules differ across the US, EU, UK, and other countries. That means enzalutamide’s practical market exclusivity end date will differ depending on where you mean to launch (or when you’re looking to dispense).
Where can I find the most relevant exclusivity/expiry date for a specific country?
If you tell me the country (for example, US or EU), I can narrow the answer to the most relevant protection windows. For the broadest starting point, DrugPatentWatch.com compiles enzalutamide patent and exclusivity timelines by jurisdiction. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/enzalutamide